Journal of Gastroenterology

, Volume 41, Issue 12, pp 1231–1236 | Cite as

A case of deep venous thrombosis associated with pegylated interferon α2b plus ribavirin treatment of chronic hepatitis C

  • Chiaki Okuse
  • Kayo Adachi
  • Yoshiki Katakura
  • Kotaro Matsunaga
  • Toshiya Ishii
  • Nobuyuki Matsumoto
  • Hiroshi Yotsuyanagi
  • Shiro Iino
  • Michihiro Suzuki
  • Fumio Itoh
Case report

Abstract

We present a case of deep venous thrombosis (DVT) during pegylated interferon (peg-IFN)-α2b plus ribavirin treatment of chronic hepatitis C (CHC). A 67-year-old man, who had been under treatment for hypertension and diabetes mellitus, was admitted to our hospital for peg-IFN-α2b plus ribavirin treatment for CHC. His serum hepatitis C virus (HCV) RNA level became undetectable 1 week after the initiation of peg-IFN-α2b plus ribavirin treatment. He suffered from severe pain, flare, and edema in both of his lower legs 6 weeks after the initiation of peg-IFN-α2b plus ribavirin treatment. He was diagnosed as having DVT because of the presence of a thrombus in the right soleus vein by ultrasonography. Peg-IFN-α2b plus ribavirin treatment was discontinued because a causal relationship between DVT and peg-IFN-α2b plus ribavirin treatment was suspected. DVT was not observed and the symptoms in both of his legs were improved after the administration of warfarin potassium. Subsequently, DVT has not recurred, and he has remained HCV-RNA negative.

Key words

chronic hepatitis C deep venous thrombosis pegylated interferon α2b plus ribavirin treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alter, HJ, Seeff, LB 2000Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcomeSemin Liver Dis201735PubMedCrossRefGoogle Scholar
  2. 2.
    Manns, MP, McHutchison, JG, Gordon, SC, Rustgi, VK, Shiffman, M, Reindollar, R,  et al. 2001Peginterferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trialLancet35895865PubMedCrossRefGoogle Scholar
  3. 3.
    Freid, MW, Shiffman, ML, Reddy, KR, Smith, C, Marinos, G, Goncales, FL,Jr,  et al. 2002Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med34797582CrossRefGoogle Scholar
  4. 4.
    Quesada, JR, Talpaz, M, Rios, A, Kurzrock, R, Gutterman, JU 1986Clinical toxicity of interferons in cancer patients: a reviewJ Clin Oncol423443PubMedGoogle Scholar
  5. 5.
    Schalm, SW, Hansen, BE, Chemello, L, Bellobuono, A, Brouwer, JT, Weiland, O,  et al. 1997Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis CJ Hepatol269616PubMedCrossRefGoogle Scholar
  6. 6.
    López JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004;349–56Google Scholar
  7. 7.
    Rosenberg, RD, Aird, WC 1999Vascular bed specific hemostasis and hypercoagulable statesN Engl J Med340155564PubMedCrossRefGoogle Scholar
  8. 8.
    Violi, F, Ferro, D, Basili, S, Artini, M, Valesini, G, Levrero, M,  et al. 1995Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosisJ Invest Med435504Google Scholar
  9. 9.
    Pawlotsky, JM, Yahia, MB, Andre, C, Voisin, MC, Intrator, L, Roudot-Thoraval, F,  et al. 1994Immunological disorders in C virus chronic active hepatitis: a prospective case–control studyHepatology198418PubMedCrossRefGoogle Scholar
  10. 10.
    Matsuda, J, Saitoh, N, Gotoh, M, Gohchi, K, Tsukamoto, M, Syoji, S,  et al. 1995High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-αAm J Gastroenterol90113841PubMedGoogle Scholar
  11. 11.
    Fimognari, FL, De Santis, A, Piccheri, C, Moscatekki, R, Gigliotti, F, Vestri, A,  et al. 2005Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosisJ Lab Clin Med14623843PubMedCrossRefGoogle Scholar
  12. 12.
    Sachdev, P 2004Homocysteine and neuropsychiatric disordersRev Bras Psiquiatr264955CrossRefGoogle Scholar
  13. 13.
    Stratta, P, Canavese, C, Dogliani, M, Thea, A, Degani, G, Mairone, L,  et al. 1993Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemiaRen Fail1555961PubMedGoogle Scholar
  14. 14.
    Honda, K, Ando, A, Endo, M, Shimizu, K, Higashihara, M, Nitta, K,  et al. 1997Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemiaAm J Kidney Dis3012330PubMedGoogle Scholar
  15. 15.
    Ravandi-Kashani, F, Cortes, J, Kantarjian, HM 1999Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia. Coincidence or true side effect?Cancer8525838PubMedCrossRefGoogle Scholar
  16. 16.
    Creutzig, A, Freund, M 1996Severe Raynoud's syndrome associated with interferon therapy. A case historyAngiology471857PubMedCrossRefGoogle Scholar
  17. 17.
    Zuber, J, Martinez, F, Droz, D, Oksenhendler, E, Legendre, C 2002For the Groupe d'Etude des Nephrologues d'Ile-de-France (Genif). Alpha-interferon-associated thrombotic microangiopathy. A clinicopathologic study of 8 patients and review of the literatureMedicine8132131PubMedCrossRefGoogle Scholar
  18. 18.
    Lacotte, L, Thierry, V, Delwail, B, Guihot, F 1999Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemiaActa Haematol1021602CrossRefGoogle Scholar
  19. 19.
    Nadir, A, Amin, A, Chalisa, N, Thiel, DH 2000Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literatureJ Viral Hepatitis746670CrossRefGoogle Scholar
  20. 20.
    Torrisi, J, Berg, C, Harter, K, Lvovsky, E, Yeung, K, Woolly, P,  et al. 1986Phase combined modality clinical trial of alpha-interferon and radiotherapyInt J Radiat Oncol Biol Phys1214536PubMedGoogle Scholar
  21. 21.
    Steineck, G, Strander, H, Carbin, BE, Borgstrom, E, Wallin, L, Achtnich, U,  et al. 1990Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trialActa Oncologica2915562PubMedGoogle Scholar
  22. 22.
    Cnudde, F, Gharakhanian, S, Luboinski, J, Dry, J, Rozenbaum, W 1991Cutaneous local necrosis following interferon injectionsInt J Dermatol30147PubMedGoogle Scholar
  23. 23.
    Durand, JM, Quiles, N, Kaplanski, G, Soubeyrand, J 1993Thrombosis and recombinant interferon-αAm J Med951156PubMedCrossRefGoogle Scholar
  24. 24.
    Nishiwaki, H, Ogura, Y, Miyamoto, K, Hiroshiba, N, Hamada, M, Honda, Y 1997Prednisolone, platelet-activating factor receptor antagonist, or superoxide dismutase reduced leukocyte entrapment induced by interferon alpha in retinal microcirculationInvest Ophthalmol Vis Sci288116Google Scholar
  25. 25.
    Sugano, S, Suzuki, T, Watanabe, M, Ohe, K, Ishii, K, Okajima, T 1998Retinal complications and plasma c5a levels during interferon alpha therapy for chronic hepatitis CAm J Gastroenterol9324414PubMedCrossRefGoogle Scholar
  26. 26.
    Fabris, P, Betterle, C, Greggio, NA, Zanchetta, R, Bosi, E, Biasin, MR,  et al. 1998Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitisJ Hepatol285147PubMedCrossRefGoogle Scholar
  27. 27.
    Jadoul, M, Piessevaux, H, Ferrant, A, Cosyns, JP, van Ypersele de Strihou, C 1995Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2bNephrol Dial Transplant101113PubMedGoogle Scholar
  28. 28.
    Canonico, PG, Kastello, MD, Cosgriff, TM, Donovan, JC, Ross, PE, Spears, CT,  et al. 1984Hematological and bone marrow effects of ribavirin in rhesus monkeysToxicol Appl Pharmacol7416372PubMedCrossRefGoogle Scholar
  29. 29.
    Enomoto, N, Sakuma, I, Asahina, H, Kurosaki, M, Murakami, T, Yamamoto, C,  et al. 1996Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infectionN Engl J Med3347781PubMedCrossRefGoogle Scholar
  30. 30.
    Zeuzem, S, Buti, M, Ferenci, P, Horsmans, Y, Cianciara, J, Ibranyi, E,  et al. 2006Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJ Hepatol4497103PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2006

Authors and Affiliations

  • Chiaki Okuse
    • 1
  • Kayo Adachi
    • 1
  • Yoshiki Katakura
    • 1
  • Kotaro Matsunaga
    • 1
  • Toshiya Ishii
    • 1
  • Nobuyuki Matsumoto
    • 1
  • Hiroshi Yotsuyanagi
    • 2
  • Shiro Iino
    • 3
  • Michihiro Suzuki
    • 1
  • Fumio Itoh
    • 1
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan
  2. 2.Division of Infectious Diseases, Department of Internal MedicineUniversity of TokyoTokyoJapan
  3. 3.Research Center for Liver DiseaseKiyokawa Medical CenterTokyoJapan

Personalised recommendations